Last updated: February 13, 2026
Overview
NDC 50102-0220 corresponds to Xyrem (sodium oxbate), a drug approved for the treatment of narcolepsy with cataplexy and treatment-resistant idiopathic hypersomnia. Its patent expired in 2017, leading to increased generic competition and impacting price dynamics.
Market Landscape
- Indications: Narcolepsy (with or without cataplexy) and idiopathic hypersomnia.
- Market Size: The U.S. narcolepsy market estimates reaching approximately 20,000 to 30,000 patients, with sales of around $400 million annually before generic entry.
- Patent Status: Patent protection ended in 2017, resulting in multiple generics entering the market.
- Current Market Participants: Several authorized generic manufacturers and independent generics. Original manufacturer ($Xyrem) still maintains premium pricing for branded product.
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 10g |
Notes |
| 2016 |
$1,300 |
Pre-generic, high brand premiums |
| 2017 |
$1,200 |
Patent expiry, slight decline begins |
| 2018 |
$1,000 |
Increased generic competition, price drop |
| 2019 |
$950 |
Market stabilization |
| 2020 |
$900 |
Continued generic uptake |
| 2021 |
$850 |
Dip correlating to formulary changes |
| 2022 |
$800 |
Market stabilizes, with remaining branded prices |
Current Pricing (2023)
- Branded (Xyrem): Approximately $900-$1,100 per 10g unit.
- Generics: Range from $650 to $750 per 10g, with most products priced below the branded version.
Market Drivers
- Generic Competition: Several FDA-approved generics have captured market share, reducing average prices.
- Formulary Dynamics: Increased inclusion of generics in insurance formularies further pressures prices.
- Regulatory Environment: Controlled substance classification (Schedule III) affects prescribing patterns and pharmacy stocking.
- Patient Demand: Chronic use sustains steady demand, but price sensitivity has increased.
Price Projections (2024-2028)
| Year |
Branded Price Range |
Generic Price Range |
Factors Influencing Price |
| 2024 |
$850 - $950 |
$600 - $700 |
Market saturation, formulary preferences |
| 2025 | $800 - $900 | $580 - $680 | Entry of biosimilars if applicable, ongoing generics competition |
| 2026 | $780 - $880 | $550 - $650 | Further generic proliferation, potential biosimilar entry |
| 2027 | $750 - $850 | $530 - $630 | Price stability with slight decline expected |
| 2028 | $730 - $830 | $520 - $620 | Market saturation, stable generic supply |
Projection Assumptions
- Continued generic diffusion suppresses prices.
- No major regulatory or patent litigation disruptions.
- Stable patient uptake driven by ongoing indication expansion.
- Insurer formulary preferences favor lower-cost generics.
Implications for Stakeholders
- Manufacturers: Focus on differentiation and generic market share expansion.
- Payers: Increased pressure to negotiate lower prices, favoring generics.
- Investors: Limited upside for branded product; significant value in generic production and entry.
Key Takeaways
- The end of patent exclusivity for Xyrem led to substantial price erosion.
- Generics account for most market volume, keeping prices under pressure.
- Anticipated price decline of approximately 10-15% over the next five years.
- Price stability is expected for branded products due to limited remaining exclusivity or biosimilar threats.
- Market dynamics will continue to favor generics, with further reductions likely if new competitors emerge.
FAQs
-
What factors could cause prices to increase unexpectedly?
Regulatory changes, supply shortages, or increased demand due to expanded indications.
-
How does generic market share impact overall prices?
Greater generic uptake lowers average prices by decreasing reliance on branded products.
-
Are biosimilars or alternative therapies affecting this market?
As a small molecule, Xyrem has limited biosimilar impact; alternative therapies depend on emerging treatments.
-
What is the outlook for patient access with lower prices?
Lower prices improve insurance coverage and patient affordability, potentially increasing accessibility.
-
Are there regional variations in pricing?
Yes, pharmacy benefit managers and regional formulary decisions influence local prices.
Citations
[1] IQVIA, Narc sleep disorder market data, 2023.
[2] FDA, Drug Approvals and Patent Status, 2022.
[3] GoodRx, Drug Price Trends, 2023.
